AVID BIOSERVICES INC.

Avid Bioservices to Participate in KeyBanc Capital Markets Life Sciences & MedTech Forum

16 Mar 2022 16:05:00 By Nasdaq GlobeNewswire

Avid Bioservices Reports Financial Results for Third Quarter Ended January 31, 2022 and Recent Developments

08 Mar 2022 16:09:16 By Nasdaq GlobeNewswire

Avid Bioservices to Report Financial Results for Third Quarter of Fiscal Year 2022 after Market Close on March 8, 2022

01 Mar 2022 16:05:01 By Nasdaq GlobeNewswire

Avid Bioservices Announces Official Opening of Second Downstream Processing Suite Within Myford North Facility

10 Jan 2022 08:05:00 By Nasdaq GlobeNewswire

Avid Bioservices Reports Financial Results for Second Quarter Ended October 31, 2021 and Recent Developments

07 Dec 2021 16:05:00 By Nasdaq GlobeNewswire

Avid Bioservices to Report Financial Results for Second Quarter of Fiscal Year 2022 After Market Close on December 7, 2021

30 Nov 2021 16:05:00 By Nasdaq GlobeNewswire

Avid Bioservices Appoints Elie G. Hanania, Ph.D., as Vice President, Process Development, Viral Vector Technologies

04 Nov 2021 08:05:00 By Nasdaq GlobeNewswire

Avid Bioservices to Join S&P SmallCap 600 Index

26 Oct 2021 08:05:00 By Nasdaq GlobeNewswire

Avid Bioservices Announces Expansion into Viral Vector Development and Manufacturing Services for Cell and Gene Therapy

14 Oct 2021 08:05:00 By Nasdaq GlobeNewswire

Avid Bioservices Appoints Matthew Kwietniak as Chief Commercial Officer

07 Oct 2021 08:05:00 By Nasdaq GlobeNewswire

Avid Bioservices Reports Financial Results for First Quarter Ended July 31, 2021 and Recent Developments

08 Sep 2021 16:05:00 By Nasdaq GlobeNewswire

Avid Bioservices to Participate at Upcoming Investor Conferences

02 Sep 2021 16:05:00 By Nasdaq GlobeNewswire

Avid Bioservices to Report Financial Results for First Quarter of Fiscal Year 2022 After Market Close on September 8, 2021

01 Sep 2021 16:05:00 By Nasdaq GlobeNewswire

Avid Bioservices Announces Appointment of Esther M. Alegria, Ph.D., to Board of Directors

01 Jul 2021 08:05:00 By Nasdaq GlobeNewswire

Avid Bioservices Reports Financial Results for Fourth Quarter and Fiscal Year Ended April 30, 2021 and Recent Developments

29 Jun 2021 16:05:00 By Nasdaq GlobeNewswire

Avid Bioservices to Report Financial Results For Quarter and Fiscal Year Ended April 30, 2021 After Market Close on June 29, 2021

22 Jun 2021 16:05:00 By Nasdaq GlobeNewswire

Avid Bioservices to Serve as Commercial Manufacturer for ADC Therapeutics’ ZYNLONTA™ (Loncastuximab Tesirine-Lpyl)

25 May 2021 08:05:00 By Nasdaq GlobeNewswire

Avid Bioservices Announces Completion of Redemption of Series E Convertible Preferred Stock

15 Apr 2021 16:05:00 By Nasdaq GlobeNewswire

Avid Bioservices to Participate in KeyBanc Capital Markets Life Sciences & MedTech Investor Forum

17 Mar 2021 08:05:00 By Nasdaq GlobeNewswire

Avid Bioservices, Inc. Announces Pricing of $125 Million Offering of Exchangeable Senior Notes

10 Mar 2021 00:20:03 By Nasdaq GlobeNewswire